CAUTION: When reading this news item please be aware that the RejuvenAir System is an Investigational device, limited by United States Federal law to investigational use only. Not for Sale in the United States of America.
Search
Recent News
- First Randomized Controlled Study with RejuvenAir® for Chronic Bronchitis shows Clinically Significant Results September 6, 2022
- CSA Medical Announces Completion of Enrollment in Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis May 13, 2021
- CSA Medical, Inc. Announces Cooper University Health Care is the 20th Clinical Site to Join the SPRAY-CB Pivotal Study for the treatment of Chronic Bronchitis April 19, 2021
- CSA Medical Announces Metered Cryospray with the RejuvenAir® System for the treatment of Chronic Bronchitis Featured at the 21st World Congress of Bronchology and Interventional Pulmonology November 23, 2020
- CSA Medical Announces Enrollment Milestone in a Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis November 11, 2020
- CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis October 22, 2020
- CSA Medical wins CE Mark approval for RejuvenAir System December 4, 2019
- Cryotherapy for COPD patients with Chronic Bronchitis approved in Europe December 2, 2019
- CSA Medical Presents Positive Feasibility Study Results for its RejuvenAir® System at the 2019 European Respiratory Society International Congress October 3, 2019
- CSA Medical Presents Positive Feasibility Study Results for its RejuvenAir® System October 3, 2019